HCC recurrence in HCV patients after liver transplantation in the DAA treatment era: SiLVER Study subgroup analysis reveals sirolimus treatment in combination with CNIs is an excellent treatment optionWerner, J. M.Hornung, M.Krah, R.Schlitt, H. J.Geissler, E. K.Journal of viral hepatitis.
149 This is in line with the findings of Toshimori et al.,152 who noted that numerous nodules, hypervascular lesions, and HFL >2 cm had a significantly higher recurrence rate. 5.3.3. TACE TACE is currently the recommended treatment method for patients with large or multinodular HCC and ...
Cumulative probabilities of recurrence were extracted from time‐to〆vent curves based on the Kaplan㎝eier method. Hazard ratios with 95% confidence intervals were estimated using univariate and multivariate Cox regressions. Results A total of 101 patients were enrolled: 83% of them were in Child㏄...
SAT-461-HCC recurrence after DAA treatment in HCV patientsdoi:10.1016/S0618-8278(19)31668-8Maria GuarinoDario BruzzeseGiovan Giuseppe Di CostanzoMarco GuarracinoFederica MorandoAnna SessaLuca RinaldiMarcello PersicoAngelo Salomone MegnaCoppola Nicola...
Method for in vitro diagnosing and prognosing of triple negative breast cancer recurrenceThe present invention is in the technical field of breast cancer management, and more particularly relates to the diagnosis and/or prognosing of triple-negative breast cancer (TNBC). The invention is more ...
Syed, TaseenAli, Ijlal AkbarMahmood, SultanFazili, JavidOfficial journal of the American College of Gastroenterology | ACG
The aim of this study was thus to assess safety and long‐term efficacy of RBV ‐free DAA combinations in HCV ‐recurrent patients after OLT . Patients & Methods A total of 62 OLT recipients (male: 50%/81%; age: 60.7?±?8.5?years [mean?±? SD ]; GT ‐ 1: 48, GT ‐ 3: 9,...
Method and apparatus for predicting prognosis of cancer recurrenceThe present invention features microRNAs as biomarkers for prognosing cancer relapse in cancer patient. The present invention also features methods, devices, and kits for this purpose.クヌーセン スティーン...
Issachar A, Sneh-Arbib O, Braun M, Shlomai A, Oxtrud E, et al. Occurrence and recurrence of malignancies post DAA Treatment in 5.1% of patients- single center experience. J Hepatol 2017;66:S97.LBP-509-Occurrence and recurrence of malignancies post DAA Treatment in 5.1%of patients-...
and at least one member of the set of radiomic features; compute a probability that the region of tissue will experience NSCLC recurrence based, at least in part, on the combined feature set; and classify the region of tissue as recurrent or non-recurrent based, at least in part, on the...